System for scoring curative effect of CDK4 / 6 inhibitor on advanced breast cancer and scoring mechanism construction method
Through the CDK4/6 inhibitor efficacy scoring system based on red blood cells, the efficacy scoring value is calculated using the cell ratio in blood samples, which solves the inaccuracy of the efficacy prediction of CDK4/6 inhibitors in the prior art, and achieves potential benefits Accurate screening and efficacy prediction of the population have improved the therapeutic effect of CDK4/6 inhibitors.
Patent Information
- Application Number
- CN202411068706.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-15
AI Technical Summary
It is difficult for the prior art to accurately screen potential benefit groups of CDK4/6 inhibitors, and there is heterogeneity in the research data on biomarkers related to the efficacy of CDK4/6 inhibitors, and more effective efficacy prediction methods are needed.
The efficacy score system of CDK4/6 inhibitor based on red blood cells is calculated by the ratio of neutrophils, lymphocytes, monocytes and platelets to red blood cells in blood samples. The scoring mechanism is constructed using the maxstat algorithm model to predict patients. poor prognosis.
Accurate scores of the efficacy of CDK4/6 inhibitors in patients were achieved, helping to accurately screen potential beneficiaries, improving the accuracy of efficacy prediction of CDK4/6 inhibitors, and indicating the value of erythrocyte immune inflammation parameters as new biomarkers.
Smart Images

Figure CN118969252A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to clinical medicine technology, and in particular to a scoring system for the efficacy of CDK4 / 6 inhibitors on advanced breast cancer and a scoring mechanism construction method. Background Art
[0002] Hormone receptor-positive breast cancer subtypes account for approximately 70% of all breast cancer cases. For decades, endocrine therapy has been the standard treatment strategy for this population. However, approximately 20% of hormone receptor-positive patients will still develop primary or acquired resistance to aromatase inhibitors (AI) or tamoxifen 10 years after receiving adjuvant therapy. Solving endocrine resistance and improving their survival outcomes are the current difficulties and hotspots of treatment. Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression. From G1 to S phase, CDK4 / 6 inhibitors block Rb protein phosphorylation by inhibiting CDK4 and CDK6, making it impossible for downstream E2F transcription factors to dissociate from Rb protein, thereby failing to initiate downstream gene transcription, preventing the cell cycle from entering S phase from G1 through the R restriction point, thereby arresting the cell cycle and preventing it from continuing to proliferate. CDK4 / 6 inhibitors combined with endocrine therapy are the first-line treatment options for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer patients (ABC). The PALOMA series of studies and the MONARCH series of studies have confirmed that the CDK4 / 6 inhibitors palbociclib and abemaciclib combined with endocrine therapy can significantly improve progression-free survival in hormone receptor-positive, HER2-negative ABC patients compared with endocrine therapy alone. However, how to accurately screen the potential beneficiaries of CDK4 / 6 inhibitors is still unclear.
[0003] At present, the results of clinical pathological factors related to the efficacy of CDK4 / 6 inhibitors are relatively consistent in different studies, but there is still a certain heterogeneity in the data of biomarker research. In the PALOMA-3 study, mRNA expression profiling analysis found that the expression of cyclin E1 was associated with resistance to palbociclib combined with fulvestrant and the reduced antiproliferative effect after palbociclib treatment. In the PALOMA-2 study, mRNA expression profiling analysis found that low expression of PD-L1 was associated with the benefit of palbociclib, and tumors with activated growth factor pathways (such as FGFR2 and ERBB3) benefited significantly after palbociclib treatment. However, a study found that activation of AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2 and loss of estrogen receptors in tumor tissues of 59 patients who had received CDK4 / 6 inhibitors may be related to the mechanism of CDK4 / 6 inhibitor resistance through whole exome sequencing. On the other hand, the popularity of gene sequencing is lower than that of liquid biopsy, so more research is still needed to further explore the efficacy prediction value of biomarkers in liquid biopsy. Summary of the invention
[0004] In view of the defects existing in the above-mentioned prior art, the technical problem to be solved by the present invention is to provide a method for scoring the efficacy of patients using CDK4 / 6 inhibitors, which is conducive to the accurate screening of potential beneficiaries of CDK4 / 6 inhibitors, and to provide a scoring system for the efficacy of CDK4 / 6 inhibitors on advanced breast cancer and a method for constructing a scoring mechanism.
[0005] In order to solve the above technical problems, the present invention provides a scoring system for the efficacy of CDK4 / 6 inhibitors on advanced breast cancer based on red blood cells, comprising:
[0006] a data processing module, for receiving blood sample test data, and calculating the ratio of the absolute value of neutrophils to the absolute value of red blood cells, the ratio of the absolute value of lymphocytes to the absolute value of red blood cells, the ratio of the absolute value of monocytes to the absolute value of red blood cells, and the ratio of the absolute value of platelets to the absolute value of red blood cells in the blood sample according to the blood sample test data;
[0007] A data prediction module, having a built-in CDK4 / 6 inhibitor efficacy prediction scoring mechanism, and a efficacy scoring value Y with an initial value of 0 is set in the data prediction module, the data prediction module is used to receive the calculation result of the data processing module, and use the built-in CDK4 / 6 inhibitor efficacy prediction scoring mechanism and the calculation result of the data processing module to calculate the efficacy scoring value Y of the blood sample provider;
[0008] The CDK4 / 6 inhibitor efficacy prediction scoring mechanism is:
[0009] If the ratio of the absolute value of neutrophils to the absolute value of red blood cells is greater than 0.96, increase the Y value by 1;
[0010] If the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is less than or equal to 0.24, increase the Y value by 1;
[0011] If the ratio of the absolute value of monocytes to the absolute value of red blood cells is greater than 0.15, increase the Y value by 1;
[0012] If the ratio of the absolute value of platelets to the absolute value of red blood cells is greater than 57.82, increase the Y value by 1;
[0013] The higher the efficacy score value Y is, the more severe the poor prognosis of the blood sample provider is.
[0014] The present invention provides a method for constructing a scoring mechanism for the efficacy of a CDK4 / 6 inhibitor on advanced breast cancer based on red blood cells, characterized in that the specific steps are as follows:
[0015] 1) Obtain sample data of blood samples from multiple patients with advanced breast cancer who have used CDK4 / 6 inhibitors;
[0016] The sample data includes the patient's baseline clinical pathological characteristics and immune-inflammatory parameters, and the immune-inflammatory parameters include the absolute value of red blood cells, the absolute value of neutrophils, the absolute value of lymphocytes, the absolute value of monocytes, and the absolute value of platelets;
[0017] 2) The ratio of the absolute value of neutrophils to the absolute value of red blood cells, the ratio of the absolute value of lymphocytes to the absolute value of red blood cells, the ratio of the absolute value of monocytes to the absolute value of red blood cells, and the ratio of the absolute value of platelets to the absolute value of red blood cells were defined as the reference values for red blood cell immune inflammation;
[0018] The time from the first administration of a CDK4 / 6 inhibitor to the first imaging-confirmed disease progression, or the time from the first administration of a CDK4 / 6 inhibitor to death, was defined as progression-free survival.
[0019] The reference values of red blood cell immune inflammation and the duration of progression-free survival of each patient in the patient sample data were input into the maxstat algorithm model, and the cutoff values of each red blood cell immune inflammation score were calculated using the maxstat algorithm;
[0020] 3) The cutoff value of the ratio of the absolute value of neutrophils to the absolute value of red blood cells in each red blood cell immune-inflammatory reference value is defined as cutoff value A, the cutoff value of the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is defined as cutoff value B, the cutoff value of the ratio of the absolute value of monocytes to the absolute value of red blood cells is defined as cutoff value C, and the cutoff value of the ratio of the absolute value of platelets to the absolute value of red blood cells is defined as cutoff value D;
[0021] Set an efficacy score value Y with an initial value of 0 to construct a CDK4 / 6 inhibitor efficacy prediction scoring mechanism. The specific scoring mechanism is:
[0022] If the ratio of the absolute value of neutrophils to the absolute value of red blood cells is greater than the threshold value A, the Y value is increased by 1;
[0023] If the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is less than or equal to the threshold value B, increase the Y value by 1;
[0024] If the ratio of the absolute value of monocytes to the absolute value of red blood cells is greater than the cut-off value C, increase the Y value by 1;
[0025] If the ratio of the absolute value of platelets to the absolute value of red blood cells is greater than the threshold value D, increase the Y value by 1;
[0026] The value of the efficacy score value Y is defined as the level of poor prognosis of the blood sample provider. The higher the level of poor prognosis, the more serious the poor prognosis of the blood sample provider.
[0027] Furthermore, the value of the cutoff value A is 0.96, the value of the cutoff value B is 0.24, the value of the cutoff value C is 0.15, and the value of the cutoff value D is 57.82.
[0028] The red blood cell-based CDK4 / 6 inhibitor efficacy prediction system for advanced breast cancer provided by the present invention adopts the ratio of the absolute value of neutrophils to the absolute value of red blood cells, the ratio of the absolute value of lymphocytes to the absolute value of red blood cells, the ratio of the absolute value of monocytes to the absolute value of red blood cells, and the ratio of the absolute value of platelets to the absolute value of red blood cells as red blood cell immune-inflammation reference values, making them new biomarkers that reflect the relative level of individual immunity, and scoring the efficacy of patients using CDK4 / 6 inhibitors, which is conducive to accurately screening the potential beneficiaries of CDK4 / 6 inhibitors. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1A-Figure 1D This is a Kaplan-Meier curve chart showing different survival outcomes corresponding to different levels of immune-inflammatory parameters based on red blood cells in patients before using CDK4 / 6 inhibitors. The red line in the figure is the low-level group, and the blue line is the high-level group;
[0030] Figure 2 This is a Kaplan-Meier curve diagram showing different survival outcomes corresponding to different levels of immune-inflammatory parameters based on red blood cells in patients before using CDK4 / 6 inhibitors. The red line in the figure is the patient group with an RBC-IMM score of 0, the blue line is the patient group with an RBC-IMM score of 1, the orange line is the patient group with an RBC-IMM score of 2, and the green line is the patient group with an RBC-IMM score of 3;
[0031] Figure 3 This is a nomogram made with 5 variables selected using the LASSO regression algorithm and cross-validation method for patients before using CDK4 / 6 inhibitors;
[0032] Figure 4 This is the ROC curve of patients in the training set who started using CDK4 / 6 inhibitors for 12 months;
[0033] Figure 5 This is the ROC curve of the patients in the training set who started using CDK4 / 6 inhibitors for 18 months;
[0034] Figure 6 This is the ROC curve of the patients in the validation set who started using CDK4 / 6 inhibitors for 12 months;
[0035] Figure 7 This is the ROC curve of the patients in the validation set who started using CDK4 / 6 inhibitors for 18 months. DETAILED DESCRIPTION
[0036] The following is a further detailed description of an embodiment of the present invention in conjunction with the accompanying drawings, but this embodiment is not intended to limit the present invention. All similar structures and similar variations of the present invention should be included in the protection scope of the present invention. The commas in the present invention represent the relationship of and, and the English letters in the present invention are case-sensitive.
[0037] Since Dr. Virchow first proposed that chronic inflammation may cause tumorigenesis, more and more studies have found that there is an interaction between systemic inflammation and the occurrence and development of tumors. Neutrophils, lymphocytes, and monocytes, as important effector cells of innate immunity, not only affect the occurrence and development of tumors in systemic immune inflammation and tumor microenvironment, but also affect the efficacy of anti-tumor drugs. Red blood cells are a double-edged sword. Although they can supply oxygen to tissues and organs to maintain the health of the body, they are also related to inflammation. Previous in vitro and in vivo studies have shown that the exposure of phosphatidylserine on the inner side of the aging erythrocyte membrane leads to the release of reactive oxygen species (ROS), and the inflammatory and hypoxic tumor microenvironment polarizes macrophages from M2 to M1. The increase of iron ions in the tumor microenvironment promotes ferroptosis. For lymphocytes, red blood cells can not only promote the recruitment of circulating lymphocytes in the vascular endothelium, but also reduce the apoptosis of T cells by inhibiting oxidative stress, thereby improving the proliferation and survival of T cells. In addition, the spectrum of cytokines in red blood cell lysates is different from that in plasma and white blood cells. For example, the level of IL-16 in red blood cells is 85 times that in plasma. By regulating cytokines such as IL-8 and vascular endothelial growth factor, red blood cells can also reduce cell apoptosis and stimulate T lymphocyte proliferation, and changes in the immune inflammatory microenvironment will also react on red blood cells and affect their normal state. Therefore, we invented relevant parameters such as the ratio of immune cells and red blood cells, making them new biomarkers that reflect the relative level of individual immunity, and such markers have not yet been studied in the prediction of the efficacy of CDK4 / 6 inhibitors.
[0038] The embodiment of the present invention provides a scoring system for the efficacy of CDK4 / 6 inhibitors on advanced breast cancer based on red blood cells, comprising:
[0039] A data processing module is used to receive blood sample test data, and calculate the ratio of the absolute value of neutrophils to the absolute value of red blood cells, the ratio of the absolute value of lymphocytes to the absolute value of red blood cells, the ratio of the absolute value of monocytes to the absolute value of red blood cells, and the ratio of the absolute value of platelets to the absolute value of red blood cells in the blood sample according to the blood sample test data;
[0040] Blood sample test data can be obtained through an optical microscope. The absolute value of red blood cells, the absolute value of neutrophils, the absolute value of lymphocytes, the absolute value of monocytes, and the absolute value of platelets refer to the actual values of red blood cells, neutrophils, lymphocytes, monocytes, and platelets per liter of blood in a routine blood test.
[0041] A data prediction module, having a built-in CDK4 / 6 inhibitor efficacy prediction scoring mechanism, and a efficacy scoring value Y with an initial value of 0 is set in the data prediction module, the data prediction module is used to receive the calculation result of the data processing module, and use the built-in CDK4 / 6 inhibitor efficacy prediction scoring mechanism and the calculation result of the data processing module to calculate the efficacy scoring value Y of the blood sample provider;
[0042] The CDK4 / 6 inhibitor efficacy prediction scoring mechanism is:
[0043] If the ratio of the absolute value of neutrophils to the absolute value of red blood cells is greater than 0.96, increase the Y value by 1;
[0044] If the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is less than or equal to 0.24, increase the Y value by 1;
[0045] If the ratio of the absolute value of monocytes to the absolute value of red blood cells is greater than 0.15, increase the Y value by 1;
[0046] If the ratio of the absolute value of platelets to the absolute value of red blood cells is greater than 57.82, increase the Y value by 1;
[0047] The higher the efficacy score value Y is, the more severe the poor prognosis of the blood sample provider is.
[0048] The embodiment of the present invention provides a method for constructing a scoring mechanism for the efficacy of a CDK4 / 6 inhibitor on advanced breast cancer based on red blood cells, and the specific steps are as follows:
[0049] 1) Obtain sample data of blood samples from multiple patients with advanced breast cancer who have used CDK4 / 6 inhibitors;
[0050] The sample data includes the patient's baseline clinical pathological characteristics and immune-inflammatory parameters, and the immune-inflammatory parameters include the absolute value of red blood cells, the absolute value of neutrophils, the absolute value of lymphocytes, the absolute value of monocytes, and the absolute value of platelets;
[0051] 2) The ratio of the absolute value of neutrophils to the absolute value of red blood cells, the ratio of the absolute value of lymphocytes to the absolute value of red blood cells, the ratio of the absolute value of monocytes to the absolute value of red blood cells, and the ratio of the absolute value of platelets to the absolute value of red blood cells were defined as the reference values for red blood cell immune inflammation;
[0052] The time from the first administration of a CDK4 / 6 inhibitor to the first occurrence of imaging-confirmed disease progression, or the time from the first administration of a CDK4 / 6 inhibitor to death, was defined as progression-free survival (PFS). Among them, imaging-confirmed disease progression was judged according to RECIST 1.1 criteria.
[0053] The reference value of red blood cell immune inflammation and the duration of progression-free survival of each patient in the patient sample data are input into the maxstat algorithm model, and the cutoff value of each red blood cell immune inflammation score value is calculated using the maxstat algorithm; the maxstat algorithm is a prior art and is recorded in many patent documents, and will not be described in detail in this embodiment; for example, the maxstat algorithm is recorded in the patent document with publication number CN117693337A;
[0054] 3) The cutoff value of the ratio of the absolute value of neutrophils to the absolute value of red blood cells in each red blood cell immune-inflammatory reference value is defined as cutoff value A, the cutoff value of the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is defined as cutoff value B, the cutoff value of the ratio of the absolute value of monocytes to the absolute value of red blood cells is defined as cutoff value C, and the cutoff value of the ratio of the absolute value of platelets to the absolute value of red blood cells is defined as cutoff value D;
[0055] Set an efficacy score value Y with an initial value of 0 to construct a CDK4 / 6 inhibitor efficacy prediction scoring mechanism. The specific scoring mechanism is:
[0056] If the ratio of the absolute value of neutrophils to the absolute value of red blood cells is greater than the threshold value A, the Y value is increased by 1;
[0057] If the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is less than or equal to the threshold value B, increase the Y value by 1;
[0058] If the ratio of the absolute value of monocytes to the absolute value of red blood cells is greater than the cut-off value C, increase the Y value by 1;
[0059] If the ratio of the absolute value of platelets to the absolute value of red blood cells is greater than the threshold value D, increase the Y value by 1;
[0060] The value of the efficacy score value Y is defined as the level of poor prognosis of the blood sample provider. The higher the level of poor prognosis, the more serious the poor prognosis of the blood sample provider.
[0061] By using the red blood cell-based CDK4 / 6 inhibitor efficacy scoring system for advanced breast cancer according to the embodiment of the present invention, it is only necessary for patients with advanced breast cancer who use CDK4 / 6 inhibitors to provide blood samples, and the absolute values of red blood cells, neutrophils, lymphocytes, monocytes, and platelets can be detected to score the efficacy of CDK4 / 6 inhibitors used by patients with advanced breast cancer and predict the degree of poor prognosis.
[0062] The present invention first selected sample data of blood samples from 100 patients with advanced breast cancer who used CDK4 / 6 inhibitors. The sample data included the baseline clinical pathological characteristics and immune inflammation parameters of the patients. The immune inflammation parameters included the absolute value of red blood cells, the absolute value of neutrophils, the absolute value of lymphocytes, the absolute value of monocytes, and the absolute value of platelets. The baseline clinical pathological characteristics of the patients included the age at the start of using CDK4 / 6 inhibitors, menstrual status, visceral involvement, liver involvement, the number of metastatic sites, the number of treatment lines of CDK4 / 6 inhibitors in the late stage, and whether chemotherapy was received in the late stage. Visceral involvement means that the viscera are affected by breast cancer and have metastatic lesions, and liver involvement means that the liver is affected by breast cancer and has metastatic lesions.
[0063] Then, the reference values of red blood cell immune inflammation and the duration of progression-free survival of each patient in the sample data of the above 100 patients were input into the maxstat algorithm model (the maxstat algorithm model uses the maxstat algorithm package of the R language), and the cutoff value of the ratio of the absolute value of neutrophils to the absolute value of red blood cells was 0.96, the cutoff value of the ratio of the absolute value of lymphocytes to the absolute value of red blood cells was 0.24, the cutoff value of the ratio of the absolute value of monocytes to the absolute value of red blood cells was 0.15, and the cutoff value of the ratio of the absolute value of platelets to the absolute value of red blood cells was 57.82;
[0064] The median follow-up time of the above 100 patients was 19.60 months (95% CI 16.93 months-22.37 months). A total of 73 patients (73%) experienced disease progression or death, and the median PFS (mPFS) was 11.37 months (95% CI 8.90-14.07 months). The basic information of the patients is shown in Table 1.
[0065] Table 1
[0066]
[0067] Table 1 (continued)
[0068]
[0069] Figure 1A-Figure 1DThis is the Kaplan-Meier curve diagram of different levels of various immune-inflammatory parameters obtained based on the sample data of the above 100 patients. The red line in the figure is the low-level group, and the blue line is the high-level group;
[0070] Figure 2 This is a Kaplan-Meier curve chart of different levels of red blood cell-based immune-inflammatory parameters obtained based on the sample data of the above 100 patients. The red line in the figure is the patient group with an RBC-IMM score of 0, the blue line is the patient group with an RBC-IMM score of 1, the orange line is the patient group with an RBC-IMM score of 2, and the green line is the patient group with an RBC-IMM score of 3;
[0071] from Figure 1A-Figure 1D It can be seen that the median PFS (mPFS) of the high-level group (less than or equal to the cut-off value 0.24) of the ratio of the absolute value of lymphocytes to the absolute value of red blood cells was better than that of the low-level group (HR=0.52, 95%CI 0.29-0.91, P=0.023, Figure 1A ); on the contrary, the median PFS (mPFS) of the group with a high level of the ratio of absolute neutrophil count to absolute red blood cell count (greater than the cut-off value of 0.96) was significantly shorter than that of the group with a low level (HR=1.98, 95%CI 1.10-3.56, P=0.023, Figure 1B ); The median PFS (mPFS) of the high-level group of monocyte absolute value and red blood cell absolute value (greater than the threshold of 0.15) was significantly inferior to that of the low-level group (HR=2.60, 95%CI 1.52-4.45, P<0.001, Figure 1C ); The median PFS (mPFS) of the high level group of platelet absolute value and red blood cell absolute value (greater than the cut-off value 57.82) was significantly inferior to that of the low level group (HR=1.73, 95%CI 1.09-2.75, P=0.020, Figure 1D ). This indicates that the parameters after red blood cell balance have a good predictive effect on the efficacy of CDK4 / 6 inhibitors. The above parameters are combined to obtain the RBC-IMM score (i.e., the efficacy score value Y based on red blood cell immune inflammation of the present invention). It is found that the higher the RBC-IMM score, the more likely the patient will have disease progression or death (HR = 1.80, 95% CI 1.39-2.33, P < 0.001, Figure 2 ).
[0072] In order to test the predictive efficacy of the embodiment of the present invention for progression-free survival (PFS), we again selected another 100 patients and divided the patients into a training set and a validation set at a ratio of 6:4; then, 20 candidate variables were screened out by the LASSO regression algorithm, and then the 5 variables with the smallest likelihood deviation were selected from the 20 candidate variables by cross-validation method. The 5 variables were: age, liver involvement, RBC_IMM score, whether chemotherapy was received in the late stage, and the number of CDK4 / 6 inhibitor treatment lines in the late stage; and a nomogram was drawn based on the selected 5 variables ( Figure 3 ), the point on the coordinate axis of each variable in the nomogram corresponds to the score of the first row, and the scores corresponding to the five variables are added to get the total score. The total score corresponds to the 12-month and 18-month survival rates below, which predict the probability of disease progression in the patient at these two time points. From the nomogram, it can be seen that the highest score is when the RBC-IMM score is 3 points, and the higher the score, the greater the probability of disease progression.
[0073] Figure 4 , Figure 5 These are the ROC curves of the patients in the training set (from the 100 patients selected for the second time) who started using CDK4 / 6 inhibitors for 12 months and 18 months. Figure 4 , Figure 5 The blue curve in the figure is the ROC curve drawn according to the patient's clinical index, and the black curve is the ROC curve drawn according to the patient's clinical index + red blood cell index; the clinical index refers to the combination of four variables: age, liver involvement, whether chemotherapy has been received in the late stage, and the number of CDK4 / 6 inhibitor treatment lines in the late stage; the clinical index + red blood cell index refers to the combination of five variables: age, liver involvement, whether chemotherapy has been received in the late stage, the number of CDK4 / 6 inhibitor treatment lines in the late stage, and RBC_IMM score;
[0074] from Figure 4 It can be seen that when the patient started using CDK4 / 6 inhibitors for 12 months, the AUC values of the ROC curve (blue curve) obtained based on the clinical index in the training set and the ROC curve (black curve) obtained based on the clinical index + red blood cell index were 0.726 and 0.773 respectively;
[0075] from Figure 5 It can be seen that when the patient started using CDK4 / 6 inhibitors for 18 months, the AUC values of the ROC curve (blue curve) obtained based on the clinical index in the training set and the ROC curve (black curve) obtained based on the clinical index + red blood cell index were 0.764 and 0.830, respectively;
[0076] Figure 6 , Figure 7These are the ROC curves of the patients in the validation set (from the 100 patients selected for the second time) who started using CDK4 / 6 inhibitors for 12 months and 18 months. Figure 6 , Figure 7 The blue curve in the figure is the ROC curve drawn according to the patient's clinical index, and the black curve is the ROC curve drawn according to the patient's clinical index + red blood cell index;
[0077] from Figure 6 It can be seen that when the patient started using CDK4 / 6 inhibitors for 12 months, the AUC values of the ROC curve (blue curve) obtained based on the clinical index in the validation set and the ROC curve (black curve) obtained based on the clinical index + red blood cell index were 0.759 and 0.913, respectively;
[0078] from Figure 7 It can be seen that when the patient started using CDK4 / 6 inhibitors for 18 months, the AUC values of the ROC curve (blue curve) obtained based on the clinical index in the training set and the ROC curve (black curve) obtained based on the clinical index + red blood cell index were 0.715 and 0.894, respectively;
[0079] The larger the AUC area under the ROC curve, the higher the accuracy of the model prediction. This shows that the accuracy of efficacy evaluation using clinical index + red blood cell index is better than that using clinical index alone.
Claims
1. A scoring system for the efficacy of CDK4 / 6 inhibitors on advanced breast cancer based on red blood cells, characterized in that: include: a data processing module, for receiving blood sample test data, and calculating the ratio of the absolute value of neutrophils to the absolute value of red blood cells, the ratio of the absolute value of lymphocytes to the absolute value of red blood cells, the ratio of the absolute value of monocytes to the absolute value of red blood cells, and the ratio of the absolute value of platelets to the absolute value of red blood cells in the blood sample according to the blood sample test data; A data prediction module, having a built-in CDK4 / 6 inhibitor efficacy prediction scoring mechanism, and a efficacy scoring value Y with an initial value of 0 is set in the data prediction module, the data prediction module is used to receive the calculation result of the data processing module, and use the built-in CDK4 / 6 inhibitor efficacy prediction scoring mechanism and the calculation result of the data processing module to calculate the efficacy scoring value Y of the blood sample provider; The CDK4 / 6 inhibitor efficacy prediction scoring mechanism is: If the ratio of the absolute value of neutrophils to the absolute value of red blood cells is greater than 0.96, increase the Y value by 1; If the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is less than or equal to 0.24, increase the Y value by 1; If the ratio of the absolute value of monocytes to the absolute value of red blood cells is greater than 0.15, increase the Y value by 1; If the ratio of the absolute value of platelets to the absolute value of red blood cells is greater than 57.82, increase the Y value by 1; The higher the efficacy score value Y is, the more severe the poor prognosis of the blood sample provider is.
2. A method for constructing a scoring mechanism for the efficacy of CDK4 / 6 inhibitors on advanced breast cancer based on red blood cells, characterized in that: The specific steps are as follows: 1) Obtain sample data of blood samples from multiple patients with advanced breast cancer who have used CDK4 / 6 inhibitors; The sample data includes the patient's baseline clinical pathological characteristics and immune-inflammatory parameters, and the immune-inflammatory parameters include the absolute value of red blood cells, the absolute value of neutrophils, the absolute value of lymphocytes, the absolute value of monocytes, and the absolute value of platelets; 2) The ratio of the absolute value of neutrophils to the absolute value of red blood cells, the ratio of the absolute value of lymphocytes to the absolute value of red blood cells, the ratio of the absolute value of monocytes to the absolute value of red blood cells, and the ratio of the absolute value of platelets to the absolute value of red blood cells were defined as the reference values for red blood cell immune inflammation; The time from the first administration of a CDK4 / 6 inhibitor to the first imaging-confirmed disease progression, or the time from the first administration of a CDK4 / 6 inhibitor to death, was defined as progression-free survival. The reference values of red blood cell immune inflammation and the duration of progression-free survival of each patient in the patient sample data were input into the maxstat algorithm model, and the cutoff values of each red blood cell immune inflammation score were calculated using the maxstat algorithm; 3) The cutoff value of the ratio of the absolute value of neutrophils to the absolute value of red blood cells in each red blood cell immune-inflammatory reference value is defined as cutoff value A, the cutoff value of the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is defined as cutoff value B, the cutoff value of the ratio of the absolute value of monocytes to the absolute value of red blood cells is defined as cutoff value C, and the cutoff value of the ratio of the absolute value of platelets to the absolute value of red blood cells is defined as cutoff value D; Set an efficacy score value Y with an initial value of 0 to construct a CDK4 / 6 inhibitor efficacy prediction scoring mechanism. The specific scoring mechanism is: If the ratio of the absolute value of neutrophils to the absolute value of red blood cells is greater than the threshold value A, the Y value is increased by 1; If the ratio of the absolute value of lymphocytes to the absolute value of red blood cells is less than or equal to the threshold value B, increase the Y value by 1; If the ratio of the absolute value of monocytes to the absolute value of red blood cells is greater than the cut-off value C, increase the Y value by 1; If the ratio of the absolute value of platelets to the absolute value of red blood cells is greater than the threshold value D, increase the Y value by 1; The value of the efficacy score value Y is defined as the level of poor prognosis of the blood sample provider. The higher the level of poor prognosis, the more serious the poor prognosis of the blood sample provider.
3. The method for constructing a scoring mechanism for the efficacy of erythrocyte-based CDK4 / 6 inhibitors on advanced breast cancer according to claim 2, characterized in that: The value of cutoff value A is 0.96, the value of cutoff value B is 0.24, the value of cutoff value C is 0.15, and the value of cutoff value D is 57.82.
